FR23C1038I2 - CYTOTOXIC ANTIBODY DIRECTED AGAINST TYPE B HEMATOPOIETIC LYMPHOID PROLIFERATIONS - Google Patents

CYTOTOXIC ANTIBODY DIRECTED AGAINST TYPE B HEMATOPOIETIC LYMPHOID PROLIFERATIONS

Info

Publication number
FR23C1038I2
FR23C1038I2 FR23C1038C FR23C1038C FR23C1038I2 FR 23C1038 I2 FR23C1038 I2 FR 23C1038I2 FR 23C1038 C FR23C1038 C FR 23C1038C FR 23C1038 C FR23C1038 C FR 23C1038C FR 23C1038 I2 FR23C1038 I2 FR 23C1038I2
Authority
FR
France
Prior art keywords
directed against
antibody directed
against type
cytotoxic antibody
proliferations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1038C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of FR23C1038I1 publication Critical patent/FR23C1038I1/en
Application granted granted Critical
Publication of FR23C1038I2 publication Critical patent/FR23C1038I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR23C1038C 2004-12-15 2023-10-20 CYTOTOXIC ANTIBODY DIRECTED AGAINST TYPE B HEMATOPOIETIC LYMPHOID PROLIFERATIONS Active FR23C1038I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0413320A FR2879204B1 (en) 2004-12-15 2004-12-15 CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
PCT/FR2005/003123 WO2006064121A2 (en) 2004-12-15 2005-12-14 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations

Publications (2)

Publication Number Publication Date
FR23C1038I1 FR23C1038I1 (en) 2023-12-08
FR23C1038I2 true FR23C1038I2 (en) 2024-05-03

Family

ID=34953790

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0413320A Active FR2879204B1 (en) 2004-12-15 2004-12-15 CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
FR23C1038C Active FR23C1038I2 (en) 2004-12-15 2023-10-20 CYTOTOXIC ANTIBODY DIRECTED AGAINST TYPE B HEMATOPOIETIC LYMPHOID PROLIFERATIONS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0413320A Active FR2879204B1 (en) 2004-12-15 2004-12-15 CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS

Country Status (15)

Country Link
US (2) US9234045B2 (en)
EP (2) EP1824887B1 (en)
JP (2) JP4999699B2 (en)
KR (3) KR20120023177A (en)
CN (1) CN101115772B (en)
AU (1) AU2005315534B2 (en)
BR (1) BRPI0519044B8 (en)
CA (1) CA2590303C (en)
DK (1) DK1824887T3 (en)
ES (1) ES2588161T3 (en)
FR (2) FR2879204B1 (en)
IL (1) IL183947A0 (en)
NL (1) NL301242I2 (en)
PL (1) PL1824887T3 (en)
WO (1) WO2006064121A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
FR2879204B1 (en) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
FR2879605B1 (en) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF THESE FORMATS
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
KR101329437B1 (en) 2005-05-13 2013-11-14 토포타겟 유케이 리미티드 Pharmaceutical formulations of hdac inhibitors
SI1912675T1 (en) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc B-cell reduction using cd37-specific and cd20-specific binding molecules
JP5377968B2 (en) 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド Histone deacetylase (HDAC) inhibitors used alone or in combination with chemotherapeutic drugs for cancer treatment
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
FR2910896B1 (en) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement MONOCLONAL ANTIBODY DIRECTED AGAINST THE LDL HUMAN RECEPTOR
FR2915398B1 (en) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "SET OF MEANS FOR THE TREATMENT OF MALIGNANT PATHOLOGY, AUTOIMMUNE DISEASE OR INFECTIOUS DISEASE"
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
CN101868446A (en) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 The synthetic method of some hydroxamic acid compound
PT2132228E (en) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
FR2940616A1 (en) * 2008-12-30 2010-07-02 Lfb Biotechnologies USE OF ANTI-CD20 ANTIBODY FOR THE TREATMENT OF INTRAOCULAR PRIMARY LYMPHOMA.
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CN105001334A (en) 2010-02-10 2015-10-28 伊缪诺金公司 CD20 antibodies and uses thereof
FR2962908A1 (en) * 2010-07-20 2012-01-27 Lfb Biotechnologies ANTI-CD20 ANTIBODY FORMULATION
FR2966043A1 (en) * 2010-10-14 2012-04-20 Lfb Biotechnologies USE OF ANTI-CD20 ANTIBODY FOR THE TREATMENT OF PRIMITIVE CEREBRAL LYMPHOMA
FR2976811A1 (en) 2011-06-22 2012-12-28 Lfb Biotechnologies USE OF A HIGH ADCC ANTI-CD20 ANTIBODY FOR THE TREATMENT OF WALDENSTROM'S DISEASE
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
FR2980110A1 (en) * 2011-09-20 2013-03-22 Lfb Biotechnologies Composition, useful for treating tumor including malignant tumor, leukemia and non-Hodgkin lymphoma, comprises bendamustine and an anti-cluster of differentiation 20 antibody, which is a monoclonal antibody
AU2013289984B2 (en) * 2012-07-13 2018-03-08 The Trustees Of The University Of Pennsylvania Use of CART19 to deplete normal B cells to induce tolerance
US9694071B2 (en) * 2012-11-02 2017-07-04 Tg Therapeutics, Inc. Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
CA3024123A1 (en) 2016-05-27 2017-11-30 Tg Therapeutics, Inc. Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
AU2017322501A1 (en) 2016-09-09 2019-03-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329503T2 (en) * 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
PL191251B1 (en) * 1997-03-14 2006-04-28 Idec Pharma Corp Method for integrating genes at specific sites of mammalian cell genome via honologous recombination and vectors for accomplishing the same
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1383800A4 (en) * 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
DK1537419T3 (en) 2002-09-13 2011-06-27 Lfb Biotechnologies Test for CD16-mediated ADCC efficacy of monoclonal and polyclonal antibodies
FR2844455B1 (en) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
FR2844513B1 (en) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement ANTIBODIES FOR ADCC AND INDUCING PRODUCTION OF CYTOKINS.
MXPA05004022A (en) 2002-10-17 2005-10-05 Genmab As Human monoclonal antibodies against cd20.
PT1572744E (en) 2002-12-16 2010-09-07 Genentech Inc Immunoglobulin variants and uses thereof
CN1542132A (en) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 Highly expressed recombinant virus containing human constant region all-antibody gene and its use for treating tumor
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
FR2879204B1 (en) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS

Also Published As

Publication number Publication date
FR2879204A1 (en) 2006-06-16
NL301242I2 (en) 2023-11-01
IL183947A0 (en) 2007-10-31
CA2590303A1 (en) 2006-06-22
KR101418695B1 (en) 2014-07-10
FR2879204B1 (en) 2007-02-16
WO2006064121A2 (en) 2006-06-22
DK1824887T3 (en) 2016-09-05
EP1824887A2 (en) 2007-08-29
JP5693440B2 (en) 2015-04-01
AU2005315534A1 (en) 2006-06-22
CN101115772A (en) 2008-01-30
WO2006064121A3 (en) 2006-08-31
US20160060350A1 (en) 2016-03-03
KR20120023177A (en) 2012-03-12
JP2008523793A (en) 2008-07-10
EP1824887B1 (en) 2016-05-25
EP2949674A1 (en) 2015-12-02
CN101115772B (en) 2012-10-17
CA2590303C (en) 2015-05-26
JP2012126724A (en) 2012-07-05
BRPI0519044B1 (en) 2020-11-17
KR20140003660A (en) 2014-01-09
FR23C1038I1 (en) 2023-12-08
BRPI0519044B8 (en) 2021-05-25
US20090053233A1 (en) 2009-02-26
KR20070102513A (en) 2007-10-18
KR101340192B1 (en) 2013-12-12
ES2588161T3 (en) 2016-10-31
AU2005315534B2 (en) 2011-11-10
BRPI0519044A2 (en) 2008-12-23
JP4999699B2 (en) 2012-08-15
US9873745B2 (en) 2018-01-23
US9234045B2 (en) 2016-01-12
PL1824887T3 (en) 2016-12-30
NL301242I1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
FR23C1038I2 (en) CYTOTOXIC ANTIBODY DIRECTED AGAINST TYPE B HEMATOPOIETIC LYMPHOID PROLIFERATIONS
FR21C1040I1 (en) ANTI-CD20 ANTIBODY FORMULATIONS
ATE527262T1 (en) NEW CYTOTOXIC AGENTS CONTAINING TOMAYMYCIN DERIVATIVES
IL189876A0 (en) Pharmaceutical formulations containing anti-cd3 antibody
NO20075628L (en) Pharmaceutical formulations
ITBO20050123A1 (en) GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
IL192104A0 (en) Stable protein formulations
IL188733A0 (en) Immunoconjugate formulations
IL199004A0 (en) Liquid anti-rabies antibody formulations
ATE469058T1 (en) CIGARETTE PACK
DE602004023367D1 (en) Modular axle arrangement
DE112005002927A5 (en) Multi-chamber packaging
FR2887530B1 (en) PACKAGING AND DISPENSING ASSEMBLY
ITMI20060108A1 (en) WRAPPER DISPSOTIVE
BRPI0613691A2 (en) filler nozzle
DK1900812T3 (en) The lipase powder composition
ZA200800146B (en) Immunoconjugate formulations
IL191150A0 (en) Cytotoxic antibodies targeting antibodies inhibiting factor viii
ES1061423Y (en) PERFECTED ASHTRAY
ES1059080Y (en) DISPENSER PACK OF CELLULOSICAL AND SIMILAR PRODUCTS.
ES1061537Y (en) ASHTRAY
ITTO20050140U1 (en) ASHTRAY
FR2881050B1 (en) DCCHOL IN THE NEW-NES
UA10548S (en) PACKAGING FOR CIGARETTES "CLASSIC"
UA12066S (en) WRAPPER